Novacure surges following LUNAR trial interim analysis acceleration Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Novocure (NVCR) up 67% after the company was informed that the pre-specified interim analysis for the LUNAR trial would be accelerated given the length of accrual and the number of events observed to date
- Altimeter Growth (AGC) up 2% after announcing Grab will become a U.S.-listed public company through a definitive business combination agreement between Grab and the company
- Cardlytics (CDLX) up 6% after announcing its intent to acquire Bridg for $350M in cash
- Moderna (MRNA) up 6% after the FDA and CDC recommended a pause in the use of Johnson & Johnson's (JNJ) COVID-19 vaccine
- Mackinac Financial (MFNC) up 51% after Nicolet Bankshares (NCBS) and the company jointly announced the execution of a definitive merger agreement, pursuant to which Nicolet will acquire Mackinac for $248M
DOWN AFTER EARNINGS -
LOWER -
- Johnson & Johnson (JNJ) down 2% after the CDC and FDA recommended a pause in its COVID-19 vaccine use following data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the vaccine
- Avenue Therapeutics (ATXI) down 17% after announcing that the FDA was still reviewing its new drug application for IV tramadol and had not provided a decision regarding the NDA
- Bally's (BALY) down 6% after announcing that the company and Gamesys Group (JKPTF) have agreed on definitive terms by which Bally's will combine with Gamesys in a deal that values the U.K. gambling company at $2.78B
- American Airlines (AAL) down 3% after guiding its Q1 revenue down 62% from last year
Symbols:
AGC NVCR CDLX MRNA MFNC FAST ATXI BALY AAL JNJ Keywords: Fly Intel, Wall Street, Top Stories, Stocks